Merck's Keytruda, or pembrolizumab, has been approved by the FDA as a first-line treatment in patients with locally advanced/metastatic urothelial carcinoma who do not respond to chemotherapy that contains cisplatin. The agency also approved Keytruda as a second-line treatment in patients with advanced/metastatic UC whose disease progressed on or after platinum-containing chemotherapy or within one year of neoadjuvant treatment with the chemotherapy.
Merck's Keytruda approved for 2 bladder cancer indications
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.